Copyright
©The Author(s) 2025.
World J Gastroenterol. Jul 28, 2025; 31(28): 109001
Published online Jul 28, 2025. doi: 10.3748/wjg.v31.i28.109001
Published online Jul 28, 2025. doi: 10.3748/wjg.v31.i28.109001
Table 3 Adverse events and patient compliance, n (%)
| Adverse events | EBAC group (n = 175) | VACa group (n = 175) | VACb group (n = 174) | P value |
| Constipation | 22 (12.6) | 17 (9.7) | 12 (6.9) | |
| Diarrhea | 9 (5.1) | 10 (5.7) | 9 (5.2) | |
| Headache | 7 (4.0) | 5 (2.9) | 7 (4.0) | |
| Bitter/abnormal taste | 3 (1.7) | 5 (2.9) | 2 (1.1) | |
| Nausea | 6 (3.4) | 4 (2.3) | 5 (2.9) | |
| Bloating/indigestion | 3 (1.7) | 1 (0.6) | 3 (1.7) | |
| Anorexia | 1 (0.6) | 5 (2.9) | 1 (0.6) | |
| Gastrointestinal hemorrhage | 1 (0.6) | 1 (0.6) | 3 (1.7) | |
| Total | 52 (36.6) | 48 (33.8) | 42 (29.6) | 0.5 |
| Unfinished studies | 19 (10.9) | 11 (6.3) | 14 (8.0) | 0.298 |
- Citation: Han RS, Hao JW, Wang T, Xin Z, Fan GX, Wang GD, Liu MM, Liu CX, Yang QZ, Yang ZW, Lv XY, Zhang C, Bian G, Meng J, Cui ZQ, Yun XJ, Cao JH, Li SH, Fan JF, Ma HG, Gao FY, Mao T, Tian ZB, Song XH, Yu YN. Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial. World J Gastroenterol 2025; 31(28): 109001
- URL: https://www.wjgnet.com/1007-9327/full/v31/i28/109001.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i28.109001